Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure
- 1China Academy of Chinese Medical Sciences, Guang’anmen Hospital
Abstract
Objective: This study aims to evaluate the cardiovascular and renal benefits of novel hypoglycemic agents, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 dual receptor agonists (GIP/GLP-1RAs) in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF).
Methods: Systematic literature searches were conducted in MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 30 April 2026. Randomized controlled trials (RCTs) for cardiovascular outcomes (CVOTs) or post hoc analyses of CVOTs comparing SGLT-2is, DPP-4is, GLP-1RAs, or GIP/GLP-1RAs in patients with T2DM and HF were selected. Network meta-analysis was used for indirect comparisons, with results presented as hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: A total of 10 RCTs and two post hoc analyses of CVOTs involving 13,886 patients were included. Compared with placebo, SGLT-2is (HR [95% CI]: 0.75 [0.68, 0.82]) and GLP-1RAs (HR [95% CI]: 0.77 [0.61, 0.97]) both significantly reduced the risk of HF-related composite endpoints in patients with T2DM and HF. No statistically significant difference was observed between SGLT-2is and GLP-1RAs (HR [95% CI]: 0.98 [0.76, 1.25]). SGLT-2is also reduced the risk of HF worsening (HR [95% CI]: 0.72 [0.53, 0.96]), HF hospitalization (HR [95% CI]: 0.74 [0.66, 0.83]), and cardiovascular (CV) death (HR [95% CI]: 0.87 [0.77, 0.98]). For all-cause death, SGLT-2is showed a trend toward reduced risk compared to placebo, but this difference did not reach statistical significance (HR [95% CI]: 0.83 [0.67, 1.02]). For the renal composite outcome, SGLT-2is did not demonstrate a statistically significant benefit (HR [95% CI]: 0.76 [0.51, 1.14]).
Conclusion: Optimal clinical management of T2DM requires a comprehensive assessment of cardiovascular and renal comorbidities. This network meta-analysis indicates that SGLT-2is significantly reduce the risk of HF-related composite endpoints and CV death in T2DM patients with HF, although their renoprotective effect does not reach statistical significance. GLP-1RAs also demonstrate beneficial effects on HF-related composite endpoints. These findings suggest that both SGLT-2is and GLP-1RAs are preferred glycemic control strategies for improving cardiovascular outcomes in T2DM patients with HF, while further evidence is needed to confirm their definitive renal benefits.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42026142123 , identifier: CRD420261421235.
Related
- Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
- Online information seeking behaviour and health outcomes among patients with hypertension, diabetes and dyslipidaemia (the 'three highs'): a scoping review protocol.
- Effects of Metformin on Clinical Outcomes After Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
- Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes
- Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients
BibTeX
@article{ye2026network,
title = {{Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure}},
author = {Xuejiao Ye and Qian Wu and Leyang Li and Mingyu Huang and Shihan Wang},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1955431},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1955431/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure
AU - Xuejiao Ye
AU - Qian Wu
AU - Leyang Li
AU - Mingyu Huang
AU - Shihan Wang
PY - 2026
DA - 2026/10/14
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1955431
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1955431/full
AB - Objective: This study aims to evaluate the cardiovascular and renal benefits of novel hypoglycemic agents, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 dual receptor agonists (GIP/GLP-1RAs) in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). Methods: Systematic literature searches were conducted in MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 30 April 2026. Randomized controlled trials (RCTs) for cardiovascular outcomes (CVOTs) or post hoc analyses of CVOTs comparing SGLT-2is, DPP-4is, GLP-1RAs, or GIP/GLP-1RAs in patients with T2DM and HF were selected. Network meta-analysis was used for indirect comparisons, with results presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Results: A total of 10 RCTs and two post hoc analyses of CVOTs involving 13,886 patients were included. Compared with placebo, SGLT-2is (HR [95% CI]: 0.75 [0.68, 0.82]) and GLP-1RAs (HR [95% CI]: 0.77 [0.61, 0.97]) both significantly reduced the risk of HF-related composite endpoints in patients with T2DM and HF. No statistically significant difference was observed between SGLT-2is and GLP-1RAs (HR [95% CI]: 0.98 [0.76, 1.25]). SGLT-2is also reduced the risk of HF worsening (HR [95% CI]: 0.72 [0.53, 0.96]), HF hospitalization (HR [95% CI]: 0.74 [0.66, 0.83]), and cardiovascular (CV) death (HR [95% CI]: 0.87 [0.77, 0.98]). For all-cause death, SGLT-2is showed a trend toward reduced risk compared to placebo, but this difference did not reach statistical significance (HR [95% CI]: 0.83 [0.67, 1.02]). For the renal composite outcome, SGLT-2is did not demonstrate a statistically significant benefit (HR [95% CI]: 0.76 [0.51, 1.14]). Conclusion: Optimal clinical management of T2DM requires a comprehensive assessment of cardiovascular and renal comorbidities. This network meta-analysis indicates that SGLT-2is significantly reduce the risk of HF-related composite endpoints and CV death in T2DM patients with HF, although their renoprotective effect does not reach statistical significance. GLP-1RAs also demonstrate beneficial effects on HF-related composite endpoints. These findings suggest that both SGLT-2is and GLP-1RAs are preferred glycemic control strategies for improving cardiovascular outcomes in T2DM patients with HF, while further evidence is needed to confirm their definitive renal benefits. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42026142123 , identifier: CRD420261421235.
SN - 1664-2392
ER -